POST-AUTHORISATION SAFETY STUDY (PASS): OBSERVATIONAL COHORT STUDY OF PAH PATIENTS NEWLY TREATED WITH EITHER UPTRAVI® (SELEXIPAG) OR ANY OTHER PAH-SPECIFIC THERAPY, IN CLINICAL PRACTICE. EXPOSURE. (EUROPEAN OBSERVATIONAL STUDY OF UPTRAVI IN REAL-LIFE).

Participantes

• Raquel López Reyes

  Investigador Principal

• Joaquín Rueda Soriano

  Investigador Principal

Grupos

• Grupo de Investigación Clínica y Traslacional en Cardiología

  

  Investigador Principal

  Esther Roselló Lletí

• Neumología

  

  Leader

  Miguel Ángel Martínez García

Financiadores - Promotores